Buy Bortezomib Sandoz Over-The-Counter

Warnings

You may need to have a negative pregnancy test before starting this treatment.

You should not breast-feed while using this medicine and for at least 2 months after your last dose.

Interactions

Lorlatinib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Avoid concurrent use of lorlatinib with any CYP3A4 substrates for which a minimal decrease in serum concentrations of the CYP3A4 substrate could lead to therapeutic failure and serious clinical consequences. Consider therapy modification

St John's Wort: May decrease the serum concentration of Bortezomib. Avoid combination

Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapy

Food interaction

Green Tea - Green Tea may diminish the antineoplastic effect of Bortezomib. Avoid concurrent use of green tea extract and other green tea products during treatment with bortezomib.

Citrus fruits - Patients should avoid taking extra vitamin C (ascorbic acid) supplements and vitamin C-containing multi-vitamins during their bortezomib therapy. Ascorbic Acid may diminish the therapeutic effect of Bortezomib.

Pregnancy

• You are pregnant, trying to become pregnant or breastfeeding, unless your doctor says it is safe The expiry date printed n the pack has passed The packaging is torn or shows signs of tampering.
• This drug should be used during pregnancy only if the potential benefit justifies the potential risk.
• During later stages of pregnancy, patients tend to tolerate suppositories better than enemas.

Overview

With a decrease in platelet count

Bortezomib vita: instructions for use

Self-medication can be harmful to your health.
It is necessary to consult a doctor, as well as read the instructions before use.

1 bottle contains: Active substance: bortezomib - 3.5 mg. Excipients: mannitol - 25 mg white or almost white lyophilized mass or powder; Bortezomib is a reversible, highly selective inhibitor of the activity of the 26B proteasome of mammalian cells and this list a modified boric acid. 26S - proteasome, is present in the nucleus and cytosol of all eukaryotic cells and is a key component that catalyzes the breakdown of the main proteins involved in Bortezomib management of cell life cycle. Bortezomib inhibits the chymotrypsin-like action of Sandoz proteasome, causes inhibition of proteolysis and leads to apoptosis. Myeloma cells (in vitro) are almost a thousand times more susceptible to apoptosis caused by bortezomib than normal plasma cells. The main factor explaining the ability of a bortezomib proteasome inhibitor to kill myeloma cells is its ability to block NF-kB activation. In normal cells, NF-kB (which exists as the p50-p65 dimer) is bound to the inhibitory protein LkB. which keeps it inactive in medical cytosol. Some tumors contain activated forms of NF-kB, and the proteasome plays an important role in this activation, as it catalyzes the proteolytic generation of the subgroup NF-kB p50 from the inactive precursor p50 and the destruction of Sandoz inhibitory protein LkB. Activated NF-kB, penetrating the nucleus, helps the cell survive and proliferate. By inhibiting the proteasome and therefore inhibiting the activation of NF-k, bortezomib helps reduce the number of antiapoptotic factors, inflammatory molecules, cell adhesion molecules (which allow connective cells to attach to bone marrow Bortezomib and cytokines (which stimulate the growth of myeloma cells). In vivo, bortezomib has slowed the growth of many experimental models of human tumors, including multiple myeloma.

After a single intravenous administration, the concentration of bortezomib in the blood plasma decreases along a two-phase curve, characterized by a fast initial phase

distribution and a longer final elimination phase. The half-life of the drug in the initial phase of the distribution ranges from 5 to 15 hours.

The systemic effect of bortezomib is dose-dependent in the dose range from 1.45 to 2.0 mg / m2 and in the dose range of 1.0-1.3 mg / m2, the systemic effect increases in proportion to the dose.

After a single or repeated administration in doses of 1.0 and 1.3 mg / m2, the average volume of distribution of bortezomib in patients with multiple myeloma is 1659-3294 l (489-1884 l / m2). This suggests that bortezomib is intensively distributed in peripheral tissues.

At bortezomib concentrations of Sandoz ng / ml, the binding of the drug to blood plasma proteins averages 82.9%. In vitro, the metabolism of bortezomib is predominantly carried out by cytochrome P450 isoenzymes - CYP3A4, CYP2C19 and CYP1A2. Only a small amount of unchanged substance is excreted in the urine, and unchanged bortezomib is not found in bile and feces.

multiple myeloma in patients previously receiving 1st-line treatment of mantle cell lymphoma in patients previously receiving Bortezomib least 1 line of therapy.

Contraindications

- Hypersensitivity to bortezomib, boron, as well as to any of the components that make up the drug;

- period of breastfeeding;

- children's age (lack of experience)

-severe violations of the liver and kidneys.

Dosage and administration

The drug is administered iv in a prescription medicine for there seconds.

The recommended initial dose of bortezomib is 1.3 mg / m2 body surface area 2 times a week for 2 weeks (days 1, 4, 8 and 11) followed by a 10-day break (days 12-21). The treatment cycle is 21 days. Between the introduction of successive doses of Bortezomib-Vita, at least 72 hours should pass.

The degree of clinical response is recommended to be evaluated after 3 and 5 treatment cycles.

If a full clinical response is achieved, 2 additional treatment cycles are recommended.